临床试验/IRCT20200105046010N46

IRCT20200105046010N46招募中未知

In- Vivo Bioequivalence study of Erlotinib tablet 150 mg Actero Pharma. with brand drug (TARCEVA® 150 mg, Rosche, Switzerland) in Iranian healthy volunteers.

Actero Pharma. Co.0 个研究点目标入组 24 人开始时间: 待定最近更新: 2022年1月11日

试验速览

阶段: 未知
状态: 招募中
发起方
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 years 至 55 years（—）
性别: All

入选标准

•General health
•Body mass index between18-28
•Informed consent
•Being at the age of 18-55 years old

排除标准

•A history of cardiovascular disease
•A history of liver & kidney disease
•Alcohol & Drug addiction
•Hypersensitivity to the drug

研究者

发起方

Actero Pharma. Co.

相似试验

In-vivo Bioequivalence Test of Erlotinib tablets with brand drug (TARCEVA® 150 mg, Rosche, Switzerland)Bio equivalence test.

IRCT20200105046010N51Abidi Pharmaceutical Company24

Bioequivalence study of erlotinib 150 mg

IRCT20200623047902N6Zistdaru Danesh Company24

In-vivo Bioequivalence Test of NEORAPA® tablet with brand drugs (AFINITOR® 10mg Novartis).In this study, the disease is not examined. Subject bioequivalence test and reference tablets Everolimus studied..

IRCT20200105046010N24ABIDI Pharmaceutical Company24

In-vivo Bioequivalence Test of Everolimus tablet with brand drugs (AFINITOR® 10mg Novartis).

IRCT20200105046010N44SOBHAN ONCOLOGY Pharmaceutical CO.24

In-vivo Bioequivalence Test of Everolimus tablet (ROLIMA® 0.75 mg) with brand drugs (CERTICAN® 0.75 mg, Novartis,Switzerlan).

IRCT20200105046010N58anoalvand Pharmaceutical Co.24